GlassScriptPhysician profile
Rebecca Nelson
NPI 1558112946
$4,068.26
in general payments reported to CMS, 2019-2025
32 companies · $3,972 in 2025
The $3,972 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $96.59 · 2025: $3,972.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,254 · Travel and Lodging: $815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,253.59 |
| Travel and Lodging | $814.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,616.55 | 2025 | Minimed 780g |
| Xeris Pharmaceuticals, INC. | $229.85 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Novo Nordisk INC | $212.32 | 2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $175.92 | 2024-2025 | |
| Corcept Therapeutics | $138.35 | 2025 | Korlym |
| Abbvie INC. | $138.03 | 2025 | |
| Insulet Corporation | $136.20 | 2025 | Omnipod |
| Abbott Laboratories | $134.71 | 2025 | Freestyle Libre 3 |
| Amgen INC. | $134.70 | 2025 | Tepezza, Repatha, Evenity |
| Ascendis Pharma Endocrinology INC | $121.39 | 2025 | Yorvipath |
| Recordati_rare_diseases_inc. | $121.22 | 2025 | Isturisa |
| Novartis Pharmaceuticals Corporation | $115.19 | 2025 | |
| Tolmar, INC. | $90.09 | 2025 | Jatenzo |
| Bayer Healthcare Pharmaceuticals INC. | $68.42 | 2025 | |
| Alexion Pharmaceuticals, INC. | $62.64 | 2025 | Strensiq |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $61.32 | 2025 | Tirosint, Flector, Licart |
| Cequr Corporation | $59.74 | 2024-2025 | Cequr Simplicity |
| Madrigal Pharmaceuticals | $56.54 | 2025 | Rezdiffra |
| Radius Health, INC. | $48.55 | 2025 | Tymlos |
| Averitas Pharma INC. | $45.97 | 2025 | Qutenza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.50 | 2025 | Jardiance |
| Lilly USA, LLC | $35.93 | 2025 | Mounjaro, Zepbound |
| Ascensia Diabetes Care US INC. | $29.18 | 2025 | |
| Neurocrine Biosciences, INC. | $28.44 | 2025 | |
| Beta Bionics, INC. | $28.12 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Sequel Med Tech, LLC | $23.29 | 2025 | Twiist |
| Kyowa Kirin, INC. | $23.14 | 2025 | |
| Astellas Pharma US INC | $20.15 | 2025 | Veozah |
| Tandem Diabetes Care, INC. | $20.09 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Mannkind Corporation | $17.73 | 2025 | |
| Lundbeck LLC | $16.32 | 2024 | Rexulti |
| Almatica Pharma LLC | $14.67 | 2025 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.